Genmab announces results from multiple clinical trials evaluating epcoritamab

Genmab announced the results from multiple clinical trials evaluating epcoritamab, an investigational subcutaneous bispecific antibody, alone or in combination with other therapies for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, R/R follicular lymphoma, previously untreated FL, and Richter’s Syndrome. These data, along with additional results from the phase 1/2 EPCORE NHL-1 clinical trial, evaluating the safety and efficacy of epcoritamab in patients with R/R large B-cell lymphoma, were presented at the 64th Annual Meeting and Exposition of the American Society of Hematology, being held in New Orleans, Louisiana, and virtually, December 10-13, 2022. Notably, results from the phase 1b/2 EPCORE NHL-2 arm evaluating 27 patients with R/R DLBCL who were eligible for autologous stem cell transplant, showed an 85 percent overall response rate and a 67 percent complete metabolic response rate, following treatment with the combination of subcutaneous epcoritamab plus standard rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin salvage therapy. Results from two additional arms of the EPCORE NHL-2 study, evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide, one arm in patients with R/R FL and the other arm in previously untreated FL, were also presented during an oral session on Sunday, December 11. In the R/R FL arm, 95 percent of efficacy evaluable patients treated with subcutaneous epcoritamab in combination with rituximab and lenalidomide achieved an overall response. Among these patients, 80 percent achieved a CMR, and 15 percent achieved a partial metabolic response. The majority of patients achieved a response at the first tumor response assessment and most continued to respond through the latest assessment at the time of data collection. In the previously untreated FL patient arm, 94 percent of efficacy evaluable patients who received subcutaneous epcoritamab in combination with rituximab and lenalidomide achieved an overall response, including 86 percent achieving a CMR as their best overall response. Preliminary results from the phase 1b/2 open-label, multi-center safety and efficacy EPCORE CLL-1 trial showed that treatment with investigational subcutaneous epcoritamab monotherapy had promising antitumor activity in 10 patients with Richter’s Syndrome, with a 60 percent ORR and a 50 percent CMR rate. Most responses were observed by the first assessment at week six.